A prospective, interventional, randomized, double blind, parallel group, placebo controlled clinical study to evaluate the efficacy & safety of ProbioSEB CSC3™ (Bacillus coagulans LBSC plus Bacillus subtilis PLSSC plus Bacillus clausii 088AE) in immunomodulation in healthy adults - NA

Advanced Enzymes Technologies Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•1) Male/female healthy individuals aged 18-65 years at the time of consent. 2) Individuals who are literate and who are willing to give voluntary written informed consent.

•1) History of consumption of drugs or dietary or probiotic supplements related to immune function within two weeks prior to screening;
•2) Known case of hypersensitivity to the study product;
•3) Known case of hypertension, diabetes mellitus; any
•history/presence of significant metabolic or autoimmune disease
•4) History/presence of acute or chronic disorders of cardiac, liver, kidney, or gastrointestinal system within last 6 months from screening;
•5) History/presence of any other acute or chronic disease requiring treatment condition, in the opinion of the investigator, which could jeopardize the study outcome;
•6) Females who are breast-feeding/ pregnant, or intend to become
•pregnant during the study.

发起方

Advanced Enzymes Technologies Ltd